{"id":"W4394062100","doi":"10.1001/jamacardio.2024.0959","title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia","year":2024,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Novo Nordisk; Arrowhead Pharmaceuticals; Esperion Therapeutics; Amgen","keywords":"Medicine; Hypertriglyceridemia; Triglyceride; Placebo; Internal medicine; Tolerability; Gastroenterology; Endocrinology; Dose-ranging study; Apolipoprotein B; Acute pancreatitis; Cholesterol; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004650446,0.000457871,0.0004805901,0.0001621061,0.0001274586,0.00024573,0.0002227408,0.0003916975,0.001697137],"category_scores_gemma":[0.0003365823,0.000140194,0.000387775,0.0001556208,0.0002317836,0.0002468463,0.0001474613,0.0007114066,0.0002117694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001811013,"about_ca_system_score_gemma":0.0004397186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003033413,"about_ca_topic_score_gemma":0.0009576975,"domain_scores_codex":[0.999896,0.00004401915,0.00001718777,0.00001513801,0.00001542354,0.00001226768],"domain_scores_gemma":[0.9998248,0.00004186477,0.00006016276,0.000007375342,0.00001341807,0.00005232981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4821495,0.01146082,0.01917395,0.0031071,0.002058276,0.0007009698,0.0001727485,0.001559265,0.1629531,0.00044937,0.003507374,0.3127075],"study_design_scores_gemma":[0.520467,0.3488051,0.07601639,0.0002596948,0.002153577,0.001791831,0.0001418375,0.003462776,0.03674382,0.0003809804,0.009725753,0.00005130711],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892567,0.007814901,0.0005594587,0.0003743519,0.00008099804,0.0005479763,0.000207844,0.00007666912,0.001080997],"genre_scores_gemma":[0.9940574,0.00296015,0.001119827,0.0004432239,0.00009695363,0.0003083288,0.0002407013,0.000005066329,0.0007683446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001697137,"threshold_uncertainty_score":0.005677462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02024560358429529,"score_gpt":0.2954680707326398,"score_spread":0.2752224671483445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}